Method for constructing human pluripotent stem cell-derived liver organoid having enhanced drug metabolic potential and liver organoid constructed by same method

Patent metadata

Field	Value
Publication number	US-12146155-B2
Application number	US-202118547750-A
Country	US
Kind code	B2
Filing date	Apr 21, 2021
Priority date	Feb 24, 2021
Publication date	Nov 19, 2024
Grant date	Nov 19, 2024

Abstract

The present invention relates to a method for constructing a human pluripotent stem cell-derived liver organoid having enhanced drug metabolic potentials and a liver organoid constructed by the method. Because differentiation is made from human induced pluripotent stem cells dedifferentiated from somatic cells of patients, the cells are easily supplied so that patient-specific liver organoids can be prepared. The organoids can similarly simulate the real human liver structure because they consist of hepatocytes, cholangiocytes, gallbladder cells, and microduct structures, have excellent expression and functions of drug metabolism enzymes, and exhibit drug toxicity, drug metabolic capability, and drug-induced cardiotoxicity. Thus, the organoids can be advantageously used as liver models for searching for pathogenesis of liver diseases and for evaluating drug stability.

First claim

What is claimed is:

1. A method of constructing a differentiated liver organoid, the method comprising:
differentiating human pluripotent stem cells into definitive endoderm cells;
differentiating the definitive endoderm cells into hepatic endoderm cells in a first medium comprising BMP4 and SB431542;
differentiating the hepatic endoderm cells into a hepatic endoderm organoid in a second medium comprising:
30 to 70 ng/ml of FGF10;
5 to 45 ng/ml of HGF;
1 to 20 mM of nicotinamide;
1 to 20 nM of [Leu 15 ]-Gastrin I human;
0.25 to 2.25 nM of N-acetyl-L-cysteine;
1 to 9 μM of A83-01;
5 to 15 μM of Forskolin; and
1 to 5 μM of CHIR99021;
wherein the second medium does not include R-spondin 1 and EGF; and

differentiating the hepatic endoderm organoid into a differentiated liver organoid in a third medium comprising iron ions, wherein the third medium does not include EGF, and wherein the differentiated liver organoid comprises biliary-like cells, gallbladder-like cells and hepatocyte-like cells.

2. The method of claim 1 , wherein the human pluripotent stem cells are human embryonic stem cells or human induced pluripotent stem cells.

3. The method of claim 1 , wherein the step of differentiating the definitive endoderm cells into the hepatic endoderm cells is conducted until a ratio of the hepatic endoderm cells to total cells reaches 95% or more.

4. The method of claim 1 , wherein the hepatic endoderm organoid is cultured in a droplet or a suspension.

5. The method of claim 1 , further comprising cryopreserving and subsequently thawing the hepatic endoderm organoid.

6. The method of claim 1 , wherein the step of differentiating the hepatic endoderm cells into the hepatic endoderm organoid takes place for a time period of from 13 days to 25 days, wherein the step of differentiating includes first generating the hepatic endoderm organoids for a time period of from 10 days to 18 days and then expanding the hepatic endoderm organoids for a time period of from 3 days to 7 days.

7. The method of claim 1 , wherein the second medium does not include Noggin.

8. The method of claim 1 , wherein the third medium comprises iron ions selected from the group consisting of ferric citrate, iron chloride, iron sulfate, ferric sulfate, iron nitrate, and pentacarbonyl iron.

9. The method of claim 8 , wherein the third medium comprises the ferric citrate at a concentration of from 10 to 30 μM.

10. The method of claim 1 , wherein the differentiated liver organoid is cultured in a droplet or a suspension.

11. The method of claim 1 , wherein the step of differentiating the hepatic endoderm organoid into the differentiated liver organoid comprises subculturing the hepatic endoderm organoid.

12. The method of claim 11 , wherein the step of subculturing the hepatic endoderm organoid takes place in the third medium, wherein the third medium does not include R spondin-1.

13. The method of claim 11 , wherein the step of subculturing the hepatic endoderm organoid takes place for a time period of from 3 days to 7 days.

14. The method of claim 1 , wherein the step of differentiating the hepatic endoderm organoid into the differentiated liver organoid takes place for a time period of from 10 days to 20 days.

Assignees

• Korea Res Inst Chemical Tech

Inventors

• Park Han-Jin
• Kim Hyemin
• Im Ilkyun
• Kim Ji-Woo

Classifications

• C12N2500/24

  Iron; Fe chelators; Transferrin · CPC title

• C12N5/0018

  Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title

• C12N2501/70

  Enzymes · CPC title

• C12N2501/39

  Steroid hormones · CPC title

• C12N2500/38

  Vitamins · CPC title